Clinical Trial Update: Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating pembrolizumab plus lenvatinib as first-line therapy for advanced melanoma has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• LENVIMA (lenvatinib)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Malignant Melanoma | Phase 3 | Status: COMPLETED | Results posted: 2024-01-17